| 摘要: |
| 目的:探讨血清胸苷激酶(TK1)水平变化在非霍奇金淋巴瘤化疗过程的临床意义。方法:采用增强化学发光法检测37例非霍奇金淋巴瘤患者在化疗前、化疗结束1 d、化疗结束后4周的血清TK1水平。结果:不同治疗期的血清TK1水平差异有统计学意义(P<0.01)。结论:血清TK1检测结果表明,在非霍奇金淋巴瘤患者化疗的临床疗效判断及复发预后中有重要的参考价值。 |
| 关键词: 胸苷激酶1 非霍奇金淋巴瘤 药物疗法 |
| DOI：10.3724/SP.J.1008.2008.01384 |
| 投稿时间：2008-08-31修订日期：2008-09-25 |
| 基金项目: |
|
| Changes of serum TK1 level during chemotherapy of patients with non-Hodgkin’s lymphoma and its significance |
| PAN Zhu-lin1,JI Xing-ying2,SHI Yan-min1 |
| (1.Department of Hematology,No.85 Hospital of PLA,Shanghai 200052,China,;2.Department of Hematology,No.411 Hospital of PLA,Shanghai 200081) |
| Abstract: |
| Objective:To understand the significance of serum TK1 level change during chemotherapy of patients with non-Hodgkin’s lymphoma.Methods: The serum TK1 levels were detected in 37 patients with non-Hodgkin’s lymphoma by enhanced chemiluminecence assay before chemotherapy and one day, four weeks after chemotherapy.Results: The changes of serum TK1 levels were significantly different at different stages of treatment (P<0.01).Conclusion: Our findings indicate that serum TK1 change might be of great value in evaluating the treatment outcomes and predicting recurrence of patients with non-Hodgkin’s lymphoma. |
| Key words: thymidine kinase 1 non-Hodgkin’s lymphoma drug therapy |
